Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 9760.121 | 1.0340 | 1.0662 | 1.0265 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 9760.121 | 1.1300 | 1.2528 | 1.0265 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.147 | uM | 9760.121 | 0.7885 | 0.5866 | 1.0265 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.736 | uM | 9760.121 | 0.3898 | -0.2012 | 1.0265 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 3.68 | uM | 9760.121 | 0.0614 | -0.8680 | 1.0265 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 18.4 | uM | 9760.121 | 0.0645 | -0.8615 | 1.0265 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 92 | uM | 9760.121 | 0.0049 | -0.9887 | 1.0265 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 10127.121 | 1.0715 | 1.1286 | 1.1088 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 10127.121 | 0.9734 | 0.9520 | 1.1088 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 10127.121 | 1.0666 | 1.1197 | 1.1088 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 10127.121 | 1.0196 | 1.0353 | 1.1088 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.147 | uM | 10127.121 | 0.6580 | 0.3713 | 1.1088 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 0.736 | uM | 10127.121 | 0.1067 | -0.7342 | 1.1088 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 3.68 | uM | 10127.121 | 0.0847 | -0.7842 | 1.1088 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 18.4 | uM | 10127.121 | 0.0599 | -0.8422 | 1.1088 | |
| SK-BR-3 | HER2amp | Luminal | Doxorubicin | TOP2 | TOP | 92 | uM | 10127.121 | 0.0039 | -0.9867 | 1.1088 | |
| SUM102PT | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 9777.121 | 0.9193 | 0.8647 | 1.2018 | |
| SUM102PT | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 9777.121 | 1.0769 | 1.1272 | 1.2018 | |
| SUM102PT | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 9777.121 | 0.8646 | 0.7719 | 1.2018 | |
| SUM102PT | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 9777.121 | 1.0309 | 1.0513 | 1.2018 | |
| SUM102PT | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.147 | uM | 9777.121 | 0.8592 | 0.7627 | 1.2018 | |
| SUM102PT | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.736 | uM | 9777.121 | 0.0926 | -0.7237 | 1.2018 | |
| SUM102PT | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 3.68 | uM | 9777.121 | 0.0395 | -0.8639 | 1.2018 | |
| SUM102PT | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 18.4 | uM | 9777.121 | 0.0349 | -0.8773 | 1.2018 | |
| SUM102PT | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 92 | uM | 9777.121 | 0.0016 | -0.9904 | 1.2018 |